The TG Therapeutics Inc (TGTX) Given Consensus Recommendation of "Buy" by Analysts

While looking at the Stock's Performance, TG Therapeutics, Inc. now shows a Weekly Performance of 91.23%, where Monthly Performance is 120.2%, Quarterly performance is 98.18%, 6 Months performance is 66.92% and yearly performance percentage is 7.6%. TG Therapeutics, Inc. got Initiated on 27-May-16 where investment firm SunTrust Initiated the stock to Buy. FBR Capital Initiates Coverage on the company's stock to Outperform on 12/01/15 by setting a price target of $29.

Therapeutics Inc (NASDAQ:TGTX) up 7.3 percent in late-afternoon trading - after already almost doubling its market value during yesterday's regular trading session. TG Therapeutics, Inc., formerly known as Manhattan Pharmaceuticals, Inc., is based in NY. (NASDAQ:TGTX) to Buy with a price target of $22. Raymond James Financial Services Advisors Inc. purchased a new stake in TG Therapeutics during the fourth quarter worth $143,000. For trailing twelve months, EPS value for the stock is $1.37. (NASDAQ:TGTX)'s shares have the potential to reach a high EPS of -0.31 per share, and a low EPS of -0.39 per share in the current quarter.

Some buy side analysts are also providing their Analysis on TG Therapeutics, Inc., where 3 analysts have rated the stock as Strong buy, 2 analysts have given a Buy signal, 0 said it's a HOLD, 0 reported it as Underperform and 0 analysts rated the stock as Sell. This scale runs from 1 to 5 where 1 represents Strong Buy and 5 represents Sell.

For the Current Quarter, 4 analysts are projecting the mean EPS to be $-0.34/share. "Due to hard economic and market conditions, ArcelorMittal has curtailed M&A and greenfield investment activity", NRI billionaire Lakshmi Mittal-led company said in its latest annual report. TGTX EPS growth this year is 15.80%. These results showed an earnings surprise of 0.02% (Thomson Reuter's data). The difference between Actual EPS and Estimated EPS was -0.19 Percent. The Market Capitalization of the company stands at 624.46 Million. The company's 50-day moving average is $5.26 and its 200 day moving average is $5.89. The Moving Average SMA50 is 108.42% while SMA200 is 68.46%. The Company has 52-week high of $11.6 and 52-week low of $4.1.

TG Therapeutics, Inc. (NASDAQ:TGTX) is now showing its ROA (Return on Assets) of -75.2%.

The stock has Return on Assets (ROA) of -75.2 percent. Inside the closing six months period the stock's performance raised 66.92% while overall yearly performance gained 7.60%. Therefore, the stated figure displays a quarterly performance of 87.16% and year to date performance of 119.35%. The Stock now has a Weekly Volatility of 12.97% and Monthly Volatility of 8.23%. The Relative Volume value measured for TG Therapeutics, Inc.

TG Therapeutics Inc. (TG) is a biopharmaceutical company focused on the acquisition development and commercialization of treatments for b-cell malignancies and autoimmune diseases. Stock exchanged hands with the total volume of 2.93 Million shares, as contrast to its average volume of 2.94 Million shares. The stock opened for trading at $10.5 and hit $11.6 on the upside, eventually ending the session at $10.9, with a gain of 6.86% or 0.7 points.

  • Zachary Reyes